Purple Biotech Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gil Efron
- Full Time Employees
- 10
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 4 Oppenheimer Street Rehovot TA Israel 7670104
- IPO Date
- Sep 3, 1978
- Website
- purple-biotech.com
- Similar Companies
- Business
- Purple Biotech Ltd. Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is an Israel-based clinical-stage biopharmaceutical company headquartered in Rehovot and founded in 1968 that develops first-in-class therapies harnessing the tumor microenvironment to overcome immune evasion and drug resistance in cancer patients. Its oncology pipeline comprises NT219, a novel small molecule dual inhibitor targeting IRS1/2 and STAT3 to block key oncogenic and resistance pathways in solid tumors including recurrent/metastatic squamous cell carcinoma of the head and neck; CM24, a humanized monoclonal antibody immune checkpoint inhibitor blocking CEACAM1 to enhance anti-tumor responses in pancreatic ductal adenocarcinoma and other indications; and the CAPTN-3 platform of conditionally activated tri-specific antibodies engaging T cells and NK cells against tumor-associated antigens, with lead candidate IM1240 (capped-CD3x5T4xNKG2A) targeting 5T4 and second candidate IM1305 (capped-CD3xTROP2xNKG2A) targeting TROP2, both advancing toward Phase 1 trials. The company operates primarily in the United States, Israel and Europe through clinical collaborations with institutions such as the University of Colorado Anschutz Medical Campus and Mount Sinai, partnerships including prior evaluations of CM24 with Bristol Myers Squibb's nivolumab, and strategic alliances with leading cancer centers. Recent developments include achieving commercially viable manufacturing yields for IM1240 and nominating IM1305 as a development candidate in Q3 2025, planning non-GLP/GLP toxicology studies, IND submission and Phase 1 initiation for IM1240 in 2026, receiving an intention to grant for a European patent on NT219 combinations with immunotherapies or MEK inhibitors, ongoing Phase 2 trials of NT219 with pembrolizumab or cetuximab, and securing funding to extend cash runway into H1 2027 as reported in November 2025 financial results.
Company News
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
Financial Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Purple Biotech (NASDAQ:PPBT)
Purple Biotech (PPBT) Expected to Announce Quarterly Earnings on Wednesday
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Purple Biotech Regains Compliance with Nasdaq
Purple Biotech Announces CEO Transition
Purple Biotech Announces Plan to Implement ADS Ratio Change
Short Interest in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Expands By 29.9%
Purple Biotech (NASDAQ:PPBT) Shares to Reverse Split on Monday, March 2nd
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Purple Biotech Reports Second Quarter 2025 Financial Results
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
Purple Biotech Reports First Quarter 2025 Financial Results
Purple Biotech Appoints Shai Lankry as Chief Financial Officer